Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 21:12:36时区推断·⟳ 抓取 21:13:12·⚡ 决策 07-28 22:07:03 +53m51s·90.8 天前
Greenland Mines获得加拿大Klotho基因疗法专利授权
加拿大专利授权扩大了KLTO-101相关知识产权覆盖，但只是专利层面的保护，不是IND获批、临床数据或商业订单。
📄 原文Investing.com↗ 原文
Greenland Mines receives Canadian patent for Klotho gene therapy
Nvidia’s rising CDS the talk of Wall Street amid circular financing fears CHARLOTTE, N.C. - Greenland Mines Ltd (NASDAQ…
不做 Greenland Mines（GRML.US）
只获得加拿大专利授权，尚无IND/临床数据/商业合同或可量化收入增量；同类专利族此前已公告且盘中股价反跌，当前没有正期望交易边界。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司两周前已公告澳大利亚Klotho基因疗法相关专利授权，说明这是同一早期专利组合的连续更新。
- Investing.com报道加拿大专利授权，但文章标题与正文主体不一致，降低了信号可用性。市场反应:GRML.US在10:05 ET附近报0.1739美元，较前收跌9.05%。
关键理由
- 加拿大专利授权扩大了KLTO-101相关知识产权覆盖，但只是专利层面的保护，不是IND获批、临床数据或商业订单。
- 公司称KLTO-101到2026年8月才开始工艺开发和生产，KLTO-202仍在GMP制造阶段、计划年底前才与FDA等监管沟通，短期收入贡献无法量化。
- GRML.US当前市值约2357万美元、股价盘中反跌9.05%，说明市场未把该专利当作可交易的正向重定价事件。
主要风险
- 正文标题与内容不一致，标题提到Nvidia CDS但正文是Greenland Mines专利，信号质量存在明显噪音。
- 公司此前2026-07-10已有澳大利亚同类Klotho基因疗法专利公告，本次更像专利组合延伸而非首次商业化突破。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部库未命中公司KLTO-101商业化、临床数据或收入敞口证据，仅有无关基因疗法行业内容。
检索:Greenland Mines GRML KLTO-101 Klotho patent gene therapy
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,226 字
Nvidia’s rising CDS the talk of Wall Street amid circular financing fears
CHARLOTTE, N.C. - Greenland Mines Ltd (NASDAQ:GRML) announced today that Innovation, Science and Economic Development Canada has granted Patent No. CA3,005,398 for technology related to a secreted splicing variant of mammal Klotho as a treatment for cognition and memory.
The patent covers technology exclusively licensed from researchers at Universitat Autònoma de Barcelona and collaborating institutions. The issued patent protects the use of human gene therapy using a nucleic acid gene sequence encoding the RNA splice variant protein called secreted Klotho or s-KL.
The patent includes 42 granted claims covering s-KL and its use in treating neurodegenerative diseases using genetic-based therapy. The claims provide protection for the synthesis of the protein from the gene, methods of delivery, and the use of s-KL in treating conditions including Alzheimer’s, Parkinson’s, Huntington’s, ALS, Dementia with Lewy bodies, Creutzfeldt-Jacob disease, Multiple Sclerosis, Ataxia telangiectasia, post-stroke Dementia, post-brain traumatic Dementia, Senile Dementia, and craniocerebral trauma.
According to the company’s press release statement, the Klotho gene gradually stops producing the protein due to epigenetic alterations that occur to DNA over a lifetime. The company states that loss of the protein causes events leading to diseases of aging.
Dr. Joseph Sinkule, the company’s founder and CEO, stated that the company has issued patents for KLTO-101 in major markets including the U.S., China and Europe. The product candidate KLTO-101 will begin process development and manufacturing in August 2026.
The company previously announced that KLTO-202 for the treatment of ALS, multiple sclerosis and other neuromuscular disorders has advanced to the GMP manufacturing stage. The company plans to begin interaction with the FDA and other regulatory authorities before the end of 2026.
Greenland Mines operates two divisions: mining operations focused on projects in Greenland, and a biotech division developing Klotho-based therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CHARLOTTE, N.C. - Greenland Mines Ltd (NASDAQ:GRML) announced today that Innovation, Science and Economic Development Canada has granted Patent No. CA3,005,398 for technology related to a secreted splicing variant of mammal Klotho as a treatment for cognition and memory.
The patent covers technology exclusively licensed from researchers at Universitat Autònoma de Barcelona and collaborating institutions. The issued patent protects the use of human gene therapy using a nucleic acid gene sequence encoding the RNA splice variant protein called secreted Klotho or s-KL.
The patent includes 42 granted claims covering s-KL and its use in treating neurodegenerative diseases using genetic-based therapy. The claims provide protection for the synthesis of the protein from the gene, methods of delivery, and the use of s-KL in treating conditions including Alzheimer’s, Parkinson’s, Huntington’s, ALS, Dementia with Lewy bodies, Creutzfeldt-Jacob disease, Multiple Sclerosis, Ataxia telangiectasia, post-stroke Dementia, post-brain traumatic Dementia, Senile Dementia, and craniocerebral trauma.
According to the company’s press release statement, the Klotho gene gradually stops producing the protein due to epigenetic alterations that occur to DNA over a lifetime. The company states that loss of the protein causes events leading to diseases of aging.
Dr. Joseph Sinkule, the company’s founder and CEO, stated that the company has issued patents for KLTO-101 in major markets including the U.S., China and Europe. The product candidate KLTO-101 will begin process development and manufacturing in August 2026.
The company previously announced that KLTO-202 for the treatment of ALS, multiple sclerosis and other neuromuscular disorders has advanced to the GMP manufacturing stage. The company plans to begin interaction with the FDA and other regulatory authorities before the end of 2026.
Greenland Mines operates two divisions: mining operations focused on projects in Greenland, and a biotech division developing Klotho-based therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。